• Histological confirmed invasive primary triple negative breast cancer≥15 mm) with any node status.

• Age ≥18 years

• Triple Negative subtype is defined below:

⁃ Hormone receptor status: the invasive tumour shall be ER- and progesterone receptor (PR) -negative \[staining present in \<10% by immunohistochemistry (IHC)\].

⁃ HER2 status: the invasive tumour shall be Human Epidermal growth factor Receptor (HER) 2-negative by the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) guidelines

• No previous systemic treatment for TNBC

• No concurrent anti-cancer treatment. Treatment with Bisphosphonates may continue.

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1

• Normal organ function as defined below:

‣ absolute white blood cell count ≥1.5 x 109/L

⁃ platelets ≥100 x 109/L

⁃ haemoglobin ≥90g/dL

⁃ total bilirubin ≤1.5 x institutional upper normal limit (UNL)/dL (≤ 3 x UNL for patients with Gilbert´s syndrome)

⁃ ASAT, ALAT, GGT and alkaline phosphatase levels \< 1.5 × institutional UNL.

⁃ albumin \>2.5mg/dL

⁃ Creatinine \< 110 μmol/L

⁃ T3, T4 and TSH (only patients with previous thyroid dysfunction)

• Patients of childbearing potential must have a negative serum or urine pregnancy test within 8 days prior to start of imatinib treatment..

• Female patients of childbearing potential must agree to usecontraceptive methods with a failure rate below 1% per year during the study treatment and at least 90 days after the last dose of imatinib.

• Patients must be able to take (swallow) an oral medication.

• Patients must be capable to understand and comply with the protocol and has signed the informed consent.